Literature DB >> 8393115

N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists.

A M MacLeod1, K J Merchant, M A Cascieri, S Sadowski, E Ber, C J Swain, R Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8393115     DOI： 10.1021/jm00066a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  9 in total

1.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

Authors:  Takashi Yamamoto; Padma Nair; Tally M Largent-Milnes; Neil E Jacobsen; Peg Davis; Shou-Wu Ma; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2011-03-02       Impact factor: 7.446

2.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.

Authors:  Ruben Vardanyan; Vlad K Kumirov; Gary S Nichol; Peg Davis; Erika Liktor-Busa; David Rankin; Eva Varga; Todd Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2011-08-24       Impact factor: 3.641

Review 3.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

4.  Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-06-15       Impact factor: 2.823

5.  Novel bifunctional peptides as opioid agonists and NK-1 antagonists.

Authors:  Padma Nair; Takashi Yamamoto; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Tally Largent; Shou-Wu Ma; Henry I Yamamura; Todd Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

6.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Tally M Largent-Milnes; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-07-02       Impact factor: 2.823

7.  Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Suneeta Tumati; Josephine Lai; Todd W Vanderah; Henry I Yamamura; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2007-05-22       Impact factor: 7.446

8.  A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Josef Vagner; Tally Largent-Milnes; Peg Davis; Shou-Wu Ma; Edita Navratilova; Sharif Moye; Suneeta Tumati; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-02-12       Impact factor: 7.446

9.  Novel NK1R-Targeted 68Ga-/177Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure-Activity Relationships.

Authors:  Joanna Matalińska; Katarzyna Kosińska; Paweł K Halik; Przemysław Koźmiński; Piotr F J Lipiński; Ewa Gniazdowska; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.